Article
Genome-Wide Interaction Analysis of Genetic Variants With Menopausal Hormone Therapy for Colorectal Cancer Risk.
Journal of the National Cancer Institute - 8 Aug 2022
Tian Yu, Kim Andre E, Bien Stephanie A, Lin Yi, Qu Conghui, Harrison Tabitha A, Carreras-Torres Robert, Díez-Obrero Virginia, Dimou Niki, Drew David A, Hidaka Akihisa, Huyghe Jeroen R, Jordahl Kristina M, Morrison John, Murphy Neil, Obón-Santacana Mireia, Ulrich Cornelia M, Ose Jennifer, Peoples Anita R, Ruiz-Narvaez Edward A, Shcherbina Anna, Stern Mariana C, Su Yu-Ru, van Duijnhoven Franzel J B, Arndt Volker, Baurley James W, Berndt Sonja I, Bishop D Timothy, Brenner Hermann, Buchanan Daniel D, Chan Andrew T, Figueiredo Jane C, Gallinger Steven, Gruber Stephen B, Harlid Sophia, Hoffmeister Michael, Jenkins Mark A, Joshi Amit D, Keku Temitope O, Larsson Susanna C, Le Marchand Loic, Li Li, Giles Graham G, Milne Roger L, Nan Hongmei, Nassir Rami, Ogino Shuji, Budiarto Arif, Platz Elizabeth A, Potter John D, Prentice Ross L, Rennert Gad, Sakoda Lori C, Schoen Robert E, Slattery Martha L, Thibodeau Stephen N, Van Guelpen Bethany, Visvanathan Kala, White Emily, Wolk Alicja, Woods Michael O, Wu Anna H, Campbell Peter T, Casey Graham, Conti David V, Gunter Marc J, Kundaje Anshul, Lewinger Juan Pablo, Moreno Victor, Newcomb Polly A, Pardamean Bens, Thomas Duncan C, Tsilidis Konstantinos K, Peters Ulrike, Gauderman W James, Hsu Li, Chang-Claude Jenny
Abstract excerpt
BACKGROUND: The use of menopausal hormone therapy (MHT) may interact with genetic variants to influence colorectal cancer (CRC) risk. METHODS: We conducted a genome-wide, gene-environment interaction between single nucleotide polymorphisms and the use of any MHT, estrogen only, and combined estrogen-progestogen therapy with CRC risk, among 28 486 postmenopausal women (11 519 CRC patients and 16 967 participants...
Read the complete abstract on PubMed